Dinalbuphine sebacate

DB15341InvestigationalSmall molecule

Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management).

Mechanism: Pharmacologically active on Kappa-type opioid receptor
Curator reviewed
Formula / weight: C₅₂H₆₈N₂O₁₀ · 881.12 g/mol (avg)
Also known as: NALBUPHINE SEBACATE

Resolves to

Compound

UNII464OXX39Y6CAS311768-81-7ChEMBLCHEMBL1823241

Structure

InChIKeyALOIOAGKUOQNID-ITCIXCFHSA-NSMILES

O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(OC(=O)CCCCCCCCC(=O)OC5=C6O[C@H]7[C@@H](O)CC[C@@]8(O)[C@H]9CC(C=C5)=C6[C@@]78CCN9CC5CCC5)C5=C4[C@@]2(CCN3CC2CCC2)[C@H]1O5

Targets

P41145OPRK1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

17Clinical trialsPhase, status and sponsor resolved per trial

1Marketed productAcross 1 country and 1 labeller

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dinalbuphine sebacate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account